Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entinostat + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
entinostat + gemcitabine + cisplatin is a combination chemotherapy regimen being investigated as a second-line treatment for unresectable locally advanced or metastatic bladder cancer. The regimen consists of entinostat, a selective class I histone deacetylase (HDAC) inhibitor, administered alongside the standard chemotherapy agents gemcitabine and cisplatin. Entinostat acts as an epigenetic modulator, aiming to reverse cisplatin resistance by targeting histone modification pathways, thereby enhancing the cytotoxic efficacy of the chemotherapy. This combination is being evaluated in clinical trials led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School to improve outcomes in patients who have progressed on prior therapies.
- Other names
- entinostat combined with chemotherapyentinostat + gemcitabine + cisplatin combination
02
Targets
RNR (Ribonucleotide reductase)HDAC1 (Histone Deacetylase 1)DNA
Beyond the preview
Go deeper on entinostat + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entinostat + gemcitabine + cisplatin.